Replies to post #129697 on Biotech Values

[DewDiligence]

…unless there is a deep discount, the watermark will be reached in a quarter sales or so and the 45% profit will be back.

That’s right. To reach the $99.1M operating-profit threshold for reverting to the old profit-share scheme during the current launch year, NVS will need to sell about $150M of its generic Lovenox. Since NVS was averaging about $250M per quarter prior to the AG launch, $150M should be easy to do in quarter or so, even with the AG on the market.

*Assuming the appellate court does not overturn the PI.